Donor safety

A small (25-kg), portable apheresis system, available in 1993, is designed to meet a wide variety of blood cell separation needs. The role of the apheresis system is to control the behavior, separation, and collection of blood components from the bowl while maintaining maximum donor safety. The system controls the flow rates of blood and components through variable pump speeds. It directs the flow of components out of the bowl, by fully automatic opening and closing of valves based on the output of the system sensors. The system monitors the separation of blood components in the bowl by an optics system that aims at the shoulder of the bowl. A sensor on the effluent line monitors the flow of components out of the bowl. 

Strauss RG. Apheresis donor safety—changes in humoral and cellular immunity. J Clin Apher 1984 2(l) 68-80. 

Sugano et al. [561,562] explored the lipid model containing several different phospholipids, closely resembling the mixture found in reconstituted brush border lipids [433,566] and demonstrated dramatically improved property predictions. The best-performing lipid composition consisted of a 3% wt/vol lipid solution in 1,7-octadiene (lipid consisting of 33% wt/wt cholesterol, 27% PC, 27% PE, 7% PS, 7% PI). The donor and acceptor compartments were adjusted in the pH interval between 5.0 and 7.4 [562]. With such a mixture, membrane retention is expected to be extensive when lipophilic drugs are assayed. The use of 1,7-octadiene in the assay was noted to require special safety precautions. 

Catalyzed hydrogen transfer from a hydrogen donor other than H2 is attractive industrially because of safety, engineering and economic concerns (1). This reaction has been extensively studied in the homogeneous phase (2) and under Meerwein-Ponndorf-Verley conditions (3). 

In the particular case studied in this paper, it is not worth carrying out the reaction under hydrogen transfer conditions to increase the amount of axial epimer, as up to 65% of the thermodynamically unfavoured alcohol can be obtained over Cu/Si02 at 60°C and 1 atm of H2 (5). However, this work shows that the use of secondary alcohols as donors is possible under very mild conditions over the same catalyst. This can be useful both for safety reasons and for operating under mild experimental conditions in order to convert sensitive molecules (such as the ones used in the synthesis of speciality chemicals that can not withstand gas phase conditions). 

The benefits of using ionic compounds in microwave-enhanced reactions led us to explore the possibility of using ionic solvents i.e. ionic liquids, as donors for both deuterium and tritium. Whilst D20 is now relatively inexpensive and available at high isotopic enrichment, tritiated water is usually employed, for safety reasons, at low isotopic incorporation (we typically use HTO at 5 or 50 Ci mLT1 specific activity corresponding to 0.2-2% isotopic incorporation). This is a serious limitation when there is a need to provide compounds at high specific activity. 

A recent trend in the pharmaceutical industry has been to harness the intrinsic tissue-protective properties of NO for improving the gastric tolerance of nonsteroidal antiinflammatory drugs (NS AIDs). This trend has led to the synthesis of hybrid, chimeric molecules containing an NSAID or aspirin moiety and a NO-donor functionality [153, 154]. One such hybrid is a NO-releasing derivative of aspirin, NCX-4016. In a doubleblind, randomized, placebo-controlled gastrointestinal safety assessment in healthy subjects, NCX-4016 (400 or 800 mg twice daily for 7 days) acted like aspirin as an inhibitor of arachidonic acid-induced platelet aggregation in vitro [155]. Whether... 

Do not use formaldehyde and formaldehyde donors as preservatives, as their safety is doubtful. 

Currently, all donors and blood preparations undergo multistage and expensive control to ensure the absence of viral contamination In this respect, the development of affordable methods of inactivation of viruses could be an important step toward safety in hemotransfusion. Currently used treatments such as UV irradiation damage therapeutic components of the blood (Williamson and Cardigan, 2003), so alternative selective approaches are needed for this purpose. Among them, chemotherapy, photochemotherapy (PCT), and photodynamic antibacterial therapy should be noted (Mohr, 2000). 

Osiris overcomes the ethical, health and practical concerns that hamper the development of other stem cell products because of its stem cell source and the great care taken to ensure safety and quality of the material. Stem cell donors are monitored for up to five years after donation to ensure their health status. This is the primary reason that Osiris has progressed into the human clinical trial phase faster than any other stem cell company [www. stemcellsinc. com]. 

Patent buy-outs are controlled by the wealthy donor (a foundation or government) rather than the country wherein the potential patient resides. One collective action problem is avoided, but the target country lacks control over one important element of the health and safety of its citizens. Unless a global mechanism is created to buy out all global pharmaceutical IP for low- and medium-income populations, then the target countries will be dependent upon continued foreign charity. 

In a penalty test, a property cf the system is modified to reduce the probability of the desired result. For example, to predict safety, a particular expl train interface may be tested with a standard donor and a more sensitive acceptor conversely, to predict reliability, a less sensitive acceptor material is used. If this probability is reduced sufficiently, it is possible to obtain mixed responses (that is, some fires and some no-fires) with samples of reasonable size, and to develop data from which the mean value of the penalty and its standard deviation (as well as confidence limits) can be established. These estimates can be used iri statistical extrapolation to estimate safety or reliability under the original design conditions. The term VARICOMP (VARIation of explosive COMPosition) was coined by J.N. Ayres for a method developed at the Naval Ordnance Lab, White Oak, in the 1950 s and early 1960 s (Ref 1)... 

Recombinant thrombopoietin is still an investigational agent. The primary focus of current clinical trials is for the treatment of chemotherapy-induced thrombocytopenia and thrombocytopenia accompanying hematologic stem cell transplantation. Other trials are looking into the possibility of administering thrombopoietin to normal donors in order to increase the number of cells recovered by platelet apheresis. Approval of the latter application will require that thrombopoietin be shown to have an excellent short- and long-term safety profile. 

---